Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Invested Capital (2016 - 2025)

Historic Return on Invested Capital for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to 0.07%.

  • Theravance Biopharma's Return on Invested Capital rose 2200.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year increase of 2200.0%. This contributed to the annual value of 0.35% for FY2024, which is 1500.0% down from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Return on Invested Capital is 0.07%, which was up 2200.0% from 0.03% recorded in Q2 2025.
  • Theravance Biopharma's Return on Invested Capital's 5-year high stood at 0.93% during Q1 2021, with a 5-year trough of 2.0% in Q3 2022.
  • For the 5-year period, Theravance Biopharma's Return on Invested Capital averaged around 0.01%, with its median value being 0.2% (2022).
  • As far as peak fluctuations go, Theravance Biopharma's Return on Invested Capital tumbled by -28900bps in 2022, and later surged by 17300bps in 2023.
  • Over the past 5 years, Theravance Biopharma's Return on Invested Capital (Quarter) stood at 0.81% in 2021, then crashed by -124bps to 0.2% in 2022, then tumbled by -37bps to 0.27% in 2023, then plummeted by -36bps to 0.37% in 2024, then surged by 82bps to 0.07% in 2025.
  • Its Return on Invested Capital was 0.07% in Q3 2025, compared to 0.03% in Q2 2025 and 0.4% in Q1 2025.